The Role of Epigenetics in the Pathogenesis and Potential Treatment of Attention Deficit Hyperactivity Disorder

被引:3
作者
Peedicayil, Jacob [1 ]
机构
[1] Christian Med Coll & Hosp, Dept Pharmacol & Clin Pharmacol, Vellore, Tamil Nadu, India
关键词
Attention deficit hyperactivity disorder; childhood; genetics; epigenetics; pathogenesis; treatment; HISTONE DEACETYLASE INHIBITORS; DEFICIT/HYPERACTIVITY DISORDER; DNA METHYLATION; MICRORNA LET-7D; ADHD SYMPTOMS; VALPROIC ACID; EXPRESSION; CHILDREN; AMPHETAMINE; DYSREGULATION;
D O I
10.2174/1570159X19666210920091036
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
There is increasing evidence that dysregulated epigenetic mechanisms of gene expression are involved in the pathogenesis of attention deficit hyperactivity disorder (ADHD). This review presents a comprehensive summary of the current state of research on the role of epigenetics in the pathogenesis of ADHD. The potential role of epigenetic drugs in the treatment of ADHD is also reviewed. Several studies suggest that there are epigenetic abnormalities in preclinical models of ADHD and in ADHD patients. Regarding DNA methylation, many studies have reported DNA hypermethylation. There is evidence that there is increased histone deacetylation in ADHD patients. Abnormalities in the expression of microRNAs (miRNAs) in ADHD patients have also been found. Some currently used drugs for treating ADHD, in addition to their more well-established mechanisms of action, have been shown to alter epigenetic mechanisms of gene expression. Clinical trials of epigenetic drugs in patients with ADHD report favorable results. These data suggest that abnormal epigenetic mechanisms of gene expression may be involved in the pathogenesis of ADHD. Drugs acting on epigenetic mechanisms may be a potential new class of drugs for treating ADHD.
引用
收藏
页码:1642 / 1650
页数:9
相关论文
共 50 条
  • [31] Treatment of attention deficit and hyperactivity disorder
    Tuchman, RF
    REVISTA DE NEUROLOGIA, 2001, 33 (03) : 210 - 215
  • [32] InforMatrix for attention deficit hyperactivity disorder
    Janknegt, Robert
    Faber, Adrianne
    Pereira, Rob Rodrigues
    Kalverdijk, Luuk J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (05) : 755 - 772
  • [33] Role of adenosine in the pathophysiology and treatment of attention deficit hyperactivity disorder
    Jia, Qingxia
    Tan, Hongwan
    Li, Tingsong
    Duan, Xiaoling
    PURINERGIC SIGNALLING, 2024,
  • [34] New potential leads in the biology and treatment of attention deficit-hyperactivity disorder
    Casey, B. J.
    Nigg, Joel T.
    Durston, Sarah
    CURRENT OPINION IN NEUROLOGY, 2007, 20 (02) : 119 - 124
  • [35] Armodafinil as a Potential Pharmacological Treatment for Attention Deficit Hyperactivity Disorder in Adults: A Review
    Lamas-Aguilar, Reyna
    Diaz-Ruiz, Araceli
    Navarro, Luz
    Miranda-Ojeda, Raul
    Martinez-Cardenas, Maria de los Angeles
    Mata-Bermudez, Alfonso
    Rios, Camilo
    CURRENT NEUROPHARMACOLOGY, 2024, 22 (11) : 1899 - 1908
  • [36] Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder
    Martinez-Raga, Jose
    Knecht, Carlos
    de Alvaro, Raquel
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2015, 11 : 1359 - 1370
  • [37] Attention-deficit/hyperactivity disorder during adulthood
    Magnin, E.
    Maurs, C.
    REVUE NEUROLOGIQUE, 2017, 173 (7-8) : 506 - 515
  • [38] Why the Diagnosis of Attention Deficit Hyperactivity Disorder Matters
    Hamed, Alaa M.
    Kauer, Aaron J.
    Stevens, Hanna E.
    FRONTIERS IN PSYCHIATRY, 2015, 6
  • [39] Attention deficit hyperactivity disorder and comorbidity: A review of literature
    Gnanavel, Sundar
    Sharma, Pawan
    Kaushal, Pulkit
    Hussain, Sharafat
    WORLD JOURNAL OF CLINICAL CASES, 2019, 7 (17) : 2420 - 2426
  • [40] Addressing Attention-Deficit/Hyperactivity Disorder in the Workplace
    Sarkis, Elias
    POSTGRADUATE MEDICINE, 2014, 126 (05) : 25 - 30